Local and systemic activationofthe whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers
- 1 May 1993
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 92 (2) , 274-283
- https://doi.org/10.1111/j.1365-2249.1993.tb03392.x
Abstract
SUMMARY: We have studied complement activation both in plasma samples and In lesional skin from palients with leukocytoclaslic cutaneous vasculitis (LCV). Enzyme immunoassay (EIA) quantification of the complement activation markers. C3d,g and fhe terminal complement complex (TCC) in plasma, showed lhal their levels were significantly increased in 66% and 55% of the patienis, respectively (n = 29) compared with healthy controls, whereas the standard measurements of C3, factor B, Clq, C4and C2 were generally within normal range. Elevations of C3d,g and TCC levels in plasma were signifieantly eorrelated. Importantly, a signifieant correlation was found between the severity of the vasculitis and both C3d,g and TCC plasma levels. Immunofluorescence studies of skin biopsy specimens demonstrated simultaneous presence of peri vascular dermal deposits of C3d,g and TCC in lesional skin from 96 Mi and 80% respectively of the patients (n= 25). There was a significant eorrelation between the intensity of the deposits of bolh markers. Clusterin, a TCC inhibitory protein, was always found at the same sites of perivascular TCC deposits, Immunofluorescence studies at the epidermal basemenl membrane zone (BMZ) revealed in each case deposits of C3d,g which were accompanied by TCC deposits in 52% of the biopsy specimens. These data demonstrate that there is a local and systemic activation of the whole complement cascade in human LCV. The presenee of both C3d,g and clusterin-associatcd TCC perivascular deposits suggests an intervention of a regulatory mechanism of local complement activation in LCV. Einally, measurement of plasma C3d,g and TCC appears to be a sensitive indicator of systemic complement activation and disease severity in LCV.Keywords
This publication has 35 references indexed in Scilit:
- What is clusterin?Clinical and Experimental Immunology, 2008
- Membrane Attack Complex (MAC) Deposits in Skin Are Not Always Accompanied by S-Protein and ClusterinJournal of Investigative Dermatology, 1992
- Expression and Characterization of Membrane Co-Factor Protein (MCP) in Human SkinJournal of Investigative Dermatology, 1991
- Association of IgA immune complex vasculitis and rheumatoid arthritisJournal of the American Academy of Dermatology, 1991
- Characterization of Decay-Accelerating Factor (DAF) in Human SkinJournal of Investigative Dermatology, 1991
- Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activityArthritis & Rheumatism, 1989
- Localization of terminal complement components, S-protein and SP-40,40 in renal biopsiesPathology, 1989
- THE QUANTITATION OF C3d BY ROUTINE METHODS AFTER THE DIRECT ABSORPTION OF HUMAN PLASMA WITH ANTI‐C3cActa Pathologica Microbiologica Scandinavica Series C: Immunology, 1985
- Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complementBioscience Reports, 1985
- The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.Annals of the Rheumatic Diseases, 1983